LPF Investment Corp

Lilly Asia Ventures (LAV) is a leading biomedical venture capital firm that specializes in the life sciences and healthcare sectors, with a significant presence in both Asia and North America. Founded in 2008 as the venture capital arm of Eli Lilly and Company, LAV transitioned into an independent investment firm in 2011 while maintaining a strong strategic relationship with its former parent. The firm manages multiple funds, frequently utilizing the "LPF Investment Corp" designation for its specific legal entities and investment vehicles. LAV's investment strategy focuses on high-growth companies in biopharmaceuticals, medical technology, diagnostics, and healthcare services, supporting innovation from early-stage startups to late-stage growth companies. With offices in Shanghai, Hong Kong, and Palo Alto, the firm provides both capital and deep industry expertise to help its portfolio companies scale globally.